| DCC3654 |
Nir-hs |
Novel highly selective and sensitive near-infrared fluorescent probe for imaging of hydrogen sulphide in living cells and mice |
|
| DCC3655 |
Nir-ii Fluorophore-h1 |
Novel precursor of bright-emission NIR-II fluorophores for in vivo tumor imaging and image-guided surgery |
|
| DCC3656 |
Nirluc2 |
NIR emitting firefly luciferin analogue, displaying dose-independent improved NIR emission even at low concentrations where the native d-luciferin substrate does not emit |
|
| DCC3657 |
Nir-o2 |
Novel NIR NIR O2˙– probe, displays superior sensitivity to NIR O2˙– and having the capability to monitor trace amounts of intracellular NIR O2˙– in AKI in vivo |
|
| DCC3658 |
Nitd008 |
Antiviral agent against KFDV, AHFV, OHFV, as well as tick-borne encephalitis virus (TBEV) and mosquito-borne flaviviruses |
|
| DCC3659 |
nitro-r-flurbiprofen |
Selective modulator of amyloid-beta peptide degradation, regulating Abeta levels |
|
| DCC3660 |
Nivocasan |
Novel pan-caspase inhibitor, potently reducing not only inflammasome-mediated interleukin-1β (IL-1β) secretion but also osteoclast differentiation in BMMs |
|
| DCC3661 |
Nizofenone Fumarate |
Neuroprotective, protecting neurons from death following cerebral anoxia (interruption of oxygen supply to the brain). |
|
| DCC3662 |
Nktr-102 |
Topoisomerase I inhibitor prodrug, slowly hydrolyzing and releasing irinotecan, increasing drug penetration into tumors and decreasing drug clearance |
|
| DCC3663 |
Nld-22 |
Novel Enterovirus 71 Inhibitor, binding to the hydrophobic pocket in VP1 to block viral infection, exhibiting excellent antiviral activity (with an EC50 of 5.056 nM and a 100% protection rate for mice at a dose of 20 mg/kg) and low toxicity |
|
| DCC3664 |
Nlrp3 Inhibitor 4b |
Novel NLRP3 inhibitor, reducing caspase-1 activation, oligomerization of ASC, and therefore, IL-1β processing, showing a significant anti-inflammatory effect and reduced mechanical hyperalgesia at 3 and 10 mg/kg (i.p.) in an in vivo mouse of gout |
|
| DCC3665 |
Nmac24 |
Novel Nm23-H1 activator, exerting cytotoxic effects on metastatic breast cancer cells by inducing mitochondrial dysfunction only under glucose starvation |
|
| DCC3666 |
nmda167-3 |
Novel inhibitor of the Gli1 transcription, inducing apoptosis in cancer cells but not in non-cancerous cells |
|
| DCC3667 |
Nmda298-1 |
Novel inhibitor of glioma-associated oncogene homologue 1 (Gli1) mediated transcription |
|
| DCC3668 |
Nmdi14 |
Novel Inhibitor of Nonsense-Mediated RNA Decay, Suppressing Nonsense p53 Mutations |
|
| DCC3669 |
N-me-aminopyrimidinone 9 |
Potent and state-dependent Nav1.7 antagonist |
|
| DCC3670 |
Nmi801 |
Novel Mdm2 inhibitor, acting as a negative regulator of p53, reducing viability in cell culture and suppressing tumor growth |
|
| DCC3671 |
nmk-td-100 |
Novel Microtubule Modulator, Blocking Mitosis and Inducing Apoptosis in HeLa Cells by Binding to Tubulin |
|
| DCC3672 |
nms859 |
Covalent and allosteric inhibitor of the ATPase VCP/p97, inducing cancer cell death |
|
| DCC3673 |
Nms-p715 Analog |
Novel selective and orally bioavailable MPS1 inhibitor |
|
| DCC3674 |
Nms-p953 |
Novel JAK2 inhibitor, displaying significant tumor growth inhibition in SET-2 xenograft tumor model, with a mechanism of action confirmed in vivo by typical modulation of known biomarkers, and with a favorable pharmacokinetic and safety profile |
|
| DCC3675 |
Nn9056 |
Novel Potent and Highly Selective, Long-Acting, Peptide-Based Cholecystokinin 1 Receptor (CCK-1R) Agonist |
|
| DCC3676 |
N-n-butyl Haloperidol Iodide |
Novel inhibitor of autophagy, protecting cardiomyocytes against hypoxia/reoxygenation injury |
|
| DCC3677 |
Nnc-38-1049 |
Novel selective histamine H3 antagonist |
|
| DCC3678 |
Nn-dnj |
Iminosugar, binding to the active site of lysosomal beta-glucosidase and stabilizing the proper folding for the catalytic form, acting as a chemical chaperone that facilitate transport and maturation of acid beta-Glu |
|
| DCC3679 |
Nnmt Inhibitor Ns1 |
Novel potent alkynyl bisubstrate inhibitor of nicotinamide N-methyltransferase (NNMT) |
|
| DCC3680 |
nnrti F2 |
Novel non-nucleoside reverse transcriptase inhibitor (NNRTI) |
|
| DCC3681 |
Nocardicin A |
Moderate antibiotic agent against a broad spectrum of gram-negative bacteria |
|
| DCC3682 |
Nocardicin G |
The universal precursor of the nocardicins |
|
| DCC3683 |
Nocathiacin I |
Natural Inhibitor of an Oncogenic RNA, targeting RNA folds in the nuclease processing site in the oncogenic, noncoding microRNA-18a, selectively inhibiting nuclease processing in vitro and in prostate cancer cells and triggering apoptosis |
|
